"The U.S. Food and Drug Administration today approved Trulance (plecanatide) for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients.
“No one medication works for all patients suffering from chronic gastrointestina"...
Reglan Injection Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Reglan Injection (metoclopramide) is a prokinetic drug used for the relief of symptoms associated with acute and recurrent diabetic gastric stasis, to prevent nausea and vomiting from chemotherapy, to prevent postoperative nausea and vomiting, to facilitate small bowel intubation, and to stimulate gastric emptying. Reglan Injection is available in generic form. Common side effects of Reglan Injection include restlessness, drowsiness, fatigue, trouble sleeping (insomnia), headache, confusion, dizziness, skin flushing, breast swelling or tenderness, nipple discharge, dry mouth, nausea, vomiting, diarrhea, constipation, skin rash or itching, or injection site reactions (pain, itching, burning, swelling or a lump).
Dose of Reglan Injection depends on the condition being treated. Reglan Injection may interact with anticholinergic drugs, narcotics, alcohol, sedatives, hypnotics, tranquilizers, monoamine oxidase inhibitors (MAOIs), digoxin, acetaminophen, tetracycline, levodopa, ethanol, or cyclosporine. Tell your doctor all medications and supplements you use. During pregnancy, Reglan Injection should be used only if prescribed. This drug passes into breast milk. Consult your doctor before breastfeeding.
Our Reglan Injection (metoclopramide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Reglan Injection FDA Prescribing Information: Side Effects
In general, the incidence of adverse reactions correlates with the dose and duration of metoclopramide administration. The following reactions have been reported, although in most instances, data do not permit an estimate of frequency:
Restlessness, drowsiness, fatigue, and lassitude may occur in patients receiving the recommended prescribed dosage of REGLAN Injection (metoclopramide injection) . Insomnia, headache, confusion, dizziness, or mental depression with suicidal ideation also may occur (see WARNINGS). In cancer chemotherapy patients being treated with 1-2 mg/kg per dose, incidence of drowsiness is about 70%. There are isolated reports of convulsive seizures without clear-cut relationship to metoclopramide. Rarely, hallucinations have been reported.
Extrapyramidal Reactions (EPS)
Acute dystonic reactions, the most common type of EPS associated with metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of metoclopramide per day. In cancer chemotherapy patients receiving 1-2 mg/kg per dose, the incidence is 2% in patients over the ages of 30-35, and 25% or higher in pediatric patients and adult patients less than 30 years of age who have not had prophylactic administration of diphenhydramine. Symptoms include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and, rarely, stridor and dyspnea possibly due to laryngospasm; ordinarily these symptoms are readily reversed by diphenhydramine (see WARNINGS).
Tardive dyskinesia most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance (see WARNINGS).
Motor restlessness (akathisia) may consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.
Neuroleptic Malignant Syndrome
Rare occurrences of neuroleptic malignant syndrome (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of hyperthermia, muscular rigidity, altered consciousness, and autonomic instability (see WARNINGS).
Nausea and bowel disturbances, primarily diarrhea.
Rarely, cases of hepatotoxicity, characterized by such findings as jaundice and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential.
Urinary frequency and incontinence.
A few cases of neutropenia, leukopenia, or agranulocytosis, generally without clear-cut relationship to metoclopramide. Methemoglobinemia in adults and especially with overdosage in neonates (see OVERDOSAGE). Sulfhemoglobinemia in adults.
Visual disturbances. Porphyria.
Transient flushing of the face and upper body, without alterations in vital signs, following high doses intravenously.
Read the entire FDA prescribing information for Reglan Injection (Metoclopramide Injection)
Additional Reglan Injection Information
- Reglan Injection Drug Interactions Center: metoclopramide hcl inj
- Reglan Injection Side Effects Center
- Reglan Injection FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.